# Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

> **NCT06680479** · PHASE1 · SUSPENDED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (estimated)

## Conditions studied

- HIV-1

## Interventions

- **BIOLOGICAL:** CH505 TF chTrimer
- **BIOLOGICAL:** 3M-052-AF
- **BIOLOGICAL:** Aluminum Hydroxide Suspension
- **OTHER:** Sodium Chloride for Injection

## Key facts

- **NCT ID:** NCT06680479
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-04-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-14
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Temporarily Closed (paused)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680479, "Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06680479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*